2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Tai-Sen Soong

Session 4 – Combating Pandemics (A)
Date: 22 July (Wednesday) 14:00 – 15:30 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform


Tai-Sen Soong

President & CEO
Senhwa Biosciences, Inc.



Dr. Soong is the President and CEO of Senhwa, which he co-founded in 2012. Leveraging a breadth of operations experience spanning 30 years, he has executive responsibility for all of the internal operations. He was the former Head of the Life Science Investment Unit in the Overseas Business Department at CDIB since 1999. Prior to joining CDIB, he was the Managing Director of Imagen Venture Holdings, Singapore.
 
While at his tenure at National University of Singapore, he successfully launched Singapore China Biotechnology Program to recruit scientists from China to assist biotechnology development in Singapore. He was also one of the first few employees of Taiwan′s Development Center for Biotechnology(DCB). During the period of 1986 -1995, he established an R & D base for commercial application of biotechnology and promoted Taiwan′s biotechnology through product development and technology transfer. He is also founding members and Board Directors of HenKan Pharmaceuticals and Medtech Tronics, Inc.
            
Dr. Soong received his Ph.D. degree in Biology from University of Illinois at Urbana-Champaign.


Speech title & Synopsis

Why CK2 is Named as a Target for Anti COVID-19 Therapeutics Development?

Silmitasertib (CX-4945) is the First in Class small molecule CK2 inhibitor, currently in several anticancer trials, including phase II study in Cholangiocarcinoma, phase I/II study in Basal Cell Carcinoma, and phase I/II study in Medulloblastoma.
 
The world wide pandemic of COVID-19 has caused the loss of many lives by now, the situation is not eased today. The trend of developing therapeutics to treat COVID-19 is by repurposing existing approved drugs and late stage development drugs to be most desirable since the discovery of any new treatment can not meet the urgent needs today.
 
Silmitasertib (CX-4945) has been shown high safety profile and tolerability in over 200 patients in phase I and II trials conducted over the past. Recently, it was tested to have strong effects to inhibit SARS-CoV-2 replication and reduction of cytokine storm. Cytokine storm is known to occur at severe stage leading to organ failure and death. By far, Silmitasertib (CX-4945) is the only drug known today to demonstrate dual actions in reduce both viral replication and cytokine storm.